This paper examines how pharmaceutical firms have responded to changes in intellectual property rights and trade …, pharmaceutical firms may rely on non-price responses. Such responses include differentiation of products across countries and … pharmaceutical firms in the EU with respect to their product portfolios is consistent with attempts to reduce parallel trade. This …